MYBPC3 and atrial fibrillation: Although several studies showed that patients with MYH7 variants had worse outcomes regarding development of atrial fibrillation and progression to advanced heart failure compared to MYBPC3 mutation carriers [25, 27], an Austrian registry found that patients with MYBPC3 mutations were significantly older, predominantly male and more likely to have implantable cardioverter-defibrillators (ICDs) compared to those with MYH7 mutations [28].